List of Zerit Xr drug patents
Zerit Xr is owned by Bristol Myers Squibb.
Zerit Xr contains Stavudine.
Zerit Xr has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Zerit Xr are:
- US7135465
Zerit Xr was authorised for market use on 31 December, 2002.
Zerit Xr is available in capsule, extended release;oral dosage forms.
Zerit Xr can be used as method for treating hiv-1 infection.
The generics of Zerit Xr are possible to be released after 18 August, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7135465 | BRISTOL MYERS SQUIBB | Sustained release beadlets containing stavudine |
Feb, 2023
(a month ago) | |
|
US7135465
(Pediatric) | BRISTOL MYERS SQUIBB | Sustained release beadlets containing stavudine |
Aug, 2023
(4 months from now) | |
Drugs and Companies using STAVUDINE ingredient
Market Authorisation Date: 31 December, 2002
Treatment: Method for treating hiv-1 infection
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ZERIT XR family patents
3
United States
1
South Africa
1
Slovakia
1
Mexico
1
Australia
1
Russia
1
Lithuania
1
Hungary
1
Latvia
1
Norway
1
Argentina
1
Brazil
1
Peru
1
Korea, Republic of
1
Poland
1
Czech Republic
1
China
1
Georgia
1
Japan
1
Bulgaria
1
Canada
1
Estonia
1
New Zealand
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic